Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | GCK | P35557 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.45 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642561 | 0.89 | MAOB (0.52) | NR4A2RAB9ANPC1MAOBMAOA | |
| SCHEMBL10396449 | 0.87 | MAOB (0.74) | NR4A2RAB9ANPC1MAOBMAOA | |
| SCHEMBL2664907 | 0.87 | RAB9A (0.56) | NR4A2RAB9ANPC1MAOBMAOA | |
| SCHEMBL1793707 | 0.84 | NR4A2 (0.65) | NR4A2RAB9ANPC1MAOBMAOA | |
| SCHEMBL1263196 | 0.84 | NR4A2 (0.78) | NR4A2RAB9ANPC1MAOBMAOA | |
| SCHEMBL2666316 | 0.83 | NR4A2 (0.53) | NR4A2RAB9ANPC1MAOBMAOA | |
| Hydrochloric Acid SCHEMBL1793710 | 0.82 | NR4A2 (0.76) | NR4A2RAB9ANPC1MAOBMAOA | |
| SCHEMBL2666376 | 0.82 | NR4A2 (0.63) | NR4A2RAB9ANPC1MAOBMAOA | |
| SCHEMBL2178820 | 0.81 | MAOB (0.58) | RAB9AMAOBMAPTHPGDKDM4E | |
| SCHEMBL2664643 | 0.81 | KMT2A (0.57) | NR4A2RAB9ANPC1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| EP-1568367-B3 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| EP-1529530-B3 | Compounds affecting glucokinase | ASTRAZENECA AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| EP-1661569-A1 | Compounds effecting glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661563-A1 | Compound effecting Glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661568-A1 | Compounds effecting Glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661567-A1 | Compounds effecting Glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1420784-B1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| EP-1568367-A1 | Compounds effecting glucokinase | AstraZeneca AB (SE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1529530-A1 | Compounds affecting glucokinase | AstraZeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20050080106-A1 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2005-04-14 | — | — | US | disclosed |
| EP-1420784-A1 | COMPOUNDS EFFECTING GLUCOKINASE | Astrazeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003015774-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080106-A1 | Compounds effecting glucokinase | GCKR, GCK, SLC5A2 | NR4A2 2186/4885RAB9A 3175/4885NPC1 1139/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | NR4A2 2186/4885RAB9A 3175/4885NPC1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.